Clinical Trial Update: Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for a CAR-T therapy targeting Igβ in relapsed/refractory B-cell non-Hodgkin's lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• CAR-T targeting Igβ (Igβ-targeted CAR-T)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | Phase 2 | Status: UNKNOWN